Pharmacologic options for managing psychosis in Parkinson's disease

David M. Roane, Dickson Jean

Research output: Contribution to journalReview articlepeer-review


Psychosis develops in as many as 40% of patients with Parkinson's disease who are treated with dopaminergic agents. In the past, options to treat psychosis were limited to reducing the dose of Parkinson's medication or adding antipsychotic medications associated with extrapyramidal side effects. Both of these approaches increased motor disability. Research and accumulating clinical experience indicate that the newer atypical antipsychotics provide a safe and effective way to manage psychosis in this patient population. For patients with combined parkinsonism and dementia, cholinesterase inhibitors may provide another option for treating psychosis.

Original languageEnglish
Pages (from-to)42-45
Number of pages4
JournalAnnals of Long-Term Care
Issue number5
StatePublished - May 2005
Externally publishedYes


Dive into the research topics of 'Pharmacologic options for managing psychosis in Parkinson's disease'. Together they form a unique fingerprint.

Cite this